However, the extract produced a significant 15% reduction in TMAO response in female participants of premenopausal age and male participants ( n = 13), indicating potential sex-dependent cardiovascular benefits from polyphenol interventions targeting the gut microbiome-TMAO pathway
Approximately 57% of patients experienced decrease in appetite, which was consistent across the PIONEER trials [35,36,37,38,39,40,41,42,43,44]
There are no shakes to drink or foods you cannot eat
The key detail for patient-facing content is that GHK-Cus status depends on the route of administration, so injectable and non-injectable forms should not be described the same way
When exenatide or liraglutide was compared to insulin therapy in patients with similar glycemic control, weight loss with GLP-1 receptor agonist treatment ranged from 1.8 to 4.1 kg, while weight gain with insulin therapy varied between 1.0 and 4.1 kg [44, 58-60]